Importantly, this analysis showed the benefit in coupling cortical trajectories based on baseline measures of amyloid deposition measured via PET or amyloid‐to‐tau ratio via CSF, which is consistent with the prevailing disease progression model of AD in which amyloid deposition precedes change in brain structure (Jack et al., 2010). The gene discussed is MAPT; the disease is amyloidosis.